Supplier News Breaks Archives
PuraMed readies launch of migraine treatment
December 21st, 2011
SCHOFIELD, Wis. – PuraMed BioScience Inc. is hatching plans for the national product launch of LipiGesic M, its clinically tested migraine headache treatment.
The company said Wednesday that this year three top headache researchers in the United States conducted a double-blind, placebo-controlled clinical trial of LipiGesic M — published in the medical journal Headache this summer — demonstrating that the product was safe, highly effective and recommended to medical professional as a first-line treatment for migraines.
"Once the study was published, we moved forward by using the published clinical data to foster our partnerships with the two largest retail chain drug stores in the USA, Walgreens and CVS," stated PuraMed president and chief executive officer Russ Mitchell. "We expect to continue to build upon these relationships and anticipate finalizing sales purchase order agreements with more chain drug and mass market outlets to provide easy product access to all migraine sufferers.
"Our next step is to educate the medical community and healthcare professionals so they become greater aware of LipiGesic M," Mitchell added.
The company said it has begun to reserve attendance to 2012 medical conferences and continued medical education (CME) events for all health care professionals with migraine patients in their practices, including neurologists, general practitioners, pharmacists, physician assistants, nurse practitioners, nurses and chiropractors.
PuraMed also has developed a "Doctor Detailing Kit" that is now being sent directly to health professionals nationwide that include samples, study data and use indications to inform doctors who are unable to attend the various conferences throughout the year.
Plans call for consumer advertising to include both testimonial and information-based newspaper, magazine, radio and cable television ads, all of which will be coordinated with PuraMed's retail partners and include special coupons and promotions to help drive customers to the stores, according to the company.
PuraMed added that it will continue to explore various options to enhance its presence on the Internet and social media sites in 2012. The company recently launched its updated LipiGesic M website located at www.lipigesic.com, as well as its corporate website at www.puramedbioscience.com, and has established its social networking sites in Twitter, Facebook and Google Plus.